Boehringer Ingelheim has established a research collaboration with the Harvard Stem Cell Institute”™s Harvard Fibrosis Network (HFN) to discover new ways of treating fibrotic diseases such as idiopathic pulmonary fibrosis (IPF), chronic kidney disease (CKD) and nonalcoholic steatohepatitis (NASH).
The HFN unites Harvard investigators in several of the University”™s schools and at Harvard-affiliated Massachusetts General Hospital and Brigham and Women”™s Hospital.
Ridgefield-based Boehringer Ingelheim is initially sponsoring three projects to explore “novel pathways and molecular targets” for the treatment of IPF, CKD and NASH.
“We strongly believe that the integration of deep medical and preclinical research expertise across multiple fibrotic disorders is centrally important for the discovery of new treatments for patients,” said Clive R. Wood, Ph.D., senior corporate vice president Discovery Research at Boehringer Ingelheim, adding that the fibrosis cluster team “will work closely together to translate new findings and chemical starting points into drug discovery programs at Boehringer Ingelheim.”
